This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Photocure Launches Allumera® A New, Dynamic Cosmetic For Achieving Timeless Skin

PRINCETON, N.J., June 20, 2011 /PRNewswire/ -- Photocure, the world leader in photodynamic technology today announced the commercial launch of Allumera in the US, the first Photodynamic Cosmetic specifically formulated to improve the overall appearance of skin, reduce outward signs of aging and minimize the appearance of pores with minimal downtime and results that last.

"There is an unmet need in the aesthetic dermatology market and by utilizing Photocure's technology Allumera fills that gap for Dermatologists and consumers who want a non-invasive method for improving the overall appearance of their skin," said Kjetil Hestdal President and CEO of Photocure.

Look Your Best At Any Age

A large consumer study was completed in the US. In a survey of study participants conducted three months after the last Allumera cosmetic treatment, the majority of women reported:
  • Their skin looked and felt more radiant.
  • Their skin felt better hydrated and smoother.
  • Their skin felt revitalized, younger-looking and more beautiful.
  • They would recommend Allumera to a friend.

Additionally, participants who received three Allumera cosmetic treatments experienced a 44% reduction in the appearance of pores, three months after the last treatment.

"Allumera is an exciting, effective new option for patients that want their skin to look refreshed and timeless, without the down time of more aggressive procedures," said Dr. Jeanine Downie, Director of Image Dermatology PC.  "The innovation Allumera brings to the non-invasive category is the reduction in the appearance of pores, with results that last."

"We are thrilled to be able to introduce Allumera as a new class of photodynamic skin care that produces beautiful results that last," said Terry Conrad, President of Photocure US. "This is an important milestone for Photocure's U.S. portfolio and we are eager to bring this exciting product to the US aesthetic dermatology market."

Allumera is available at aesthetic dermatology offices that offer cosmetic procedures.

After Allumera application, it is recommended that patients protect exposed skin from direct sun contact for 48 hours.  Some patients may experience mild redness, slight swelling or dryness, which typically disappears within two days. Brings Dynamic Skin Care To Life

As part of the launch of Allumera, an interactive web platform, for consumers and aesthetic dermatologists has been created. The site provides valuable information about Photodynamic Cosmetics and what Allumera can do for overall aesthetic improvement.  Site visitors can also review study results, a before-and-after photo gallery, download consumer brochures and video testimonials.  A well trained customer service team can be reached at 1-855-Allumera, to answer questions and provide additional information about Allumera.

About Photocure US

Photocure US is the US subsidiary of Photocure ASA, located in Princeton, NJ and will focus on the area of dermatology. Allumera is the company's first cosmetic product introduction.

About Photocure ASA

Photocure ASA is a worldwide leader in photodynamic technology.  Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology™.  Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis.  Photocure's bladder cancer diagnostic product, Hexvix® is approved in the European Union and the US.  Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology™ is continuously being tested for new products and applications in cancer and dermatology.  Allumera, Photocure® and Hexvix® are registered trademarks of Photocure ASA.  For more information about Photocure, visit our website at

SOURCE Photocure ASA

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.29 +33.54 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,836.1350 +25.3470 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs